Meridian Bioscience, Inc.
Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae
CINCINNATI, 2016-04-28 08:00 CEST (GLOBE NEWSWIRE) --
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has receivedtheCE Markfor a new molecular diagnostic test forMycoplasma pneumonia(M. pneumoniae). The new and improvedillumigeneMycoplasma Direct assay features a simplified procedure compared to the existingillumigeneMycoplasma product. The new procedure will significantly expand Meridian’s customer base by eliminating the need for specialized techniques and training, as well as providing definitive results in less than one hour.
The launch ofillumigeneMycoplasma Direct adds to the already robustillumigenemenu that includes molecular tests forGroup AStreptococcus,Pertussis,C. difficile, Chlamydia, Gonorrhea, HSV 1&2, Group BStreptococcus, and Malaria. Allillumigene products are distributed in the EMEA regions by Meridian Bioscience Europe and in additional international markets by the Company’s global distribution network.
Mike Shaughnessy, Executive Vice President and President of Meridian Global Diagnostics stated, “We are excited to improve upon the only CE-marked and FDA-cleared stand-alone molecular assay forMycoplasma pneumoniae(illumigeneMycoplasma). By simplifying the procedure we are able to provide more customers with a superior diagnostic tool that will improve patient care. Due to the lack of cell wall in Mycoplasma, typical antibiotics like penicillin and cephalosporin are not effective, making rapid, targeted detection for appropriate treatment of the utmost importance.”
Often referred to as “walking pneumonia”,M. pneumoniaeis associated with up to 40% of community-acquired pneumonias and has been increasingly prevalent in the majority of data-reporting European countries. Infection occurs in both children and adults without geographical, gender or climate-related restrictions.M. pneumoniaeis most often associated with atypical pneumonia, presenting with symptoms that include headache, malaise, fever and sore throat accompanied by dry, paroxysmal cough.
illumigeneMycoplasma Direct is effective immediately as symptoms appear, by amplifying the specific DNA for the detection ofactiveMycoplasma pneumoniaeinfection. This represents a significant advancement in improving healthcare diagnoses and outcomes by providing a fast and definitive result, thus helping to ensure that patients receive the appropriate antibiotic therapy in a timely manner.M. pneumoniaebacterial culture lacks sensitivity and is often impractical for patient management as the organism may take as long as up to six weeks to culture. The ability to avoid treating patients empirically will reduce the administration of broad spectrum antibiotics and the likelihood of antimicrobial resistance.
TheillumigeneMycoplasma test utilizes throat swabs and provides highly sensitive and specific results. It requires no expensive capital equipment or service contract. The test relies upon a simple procedure that takes less than two minutes of hands on time. The simplicity of this technology, along with its cost efficiency and small footprint, makes this innovative test ideal for enabling a more rapid diagnosis; providing earlier identification of outbreaks and prevention of secondary cases though implementation of control measures.
About Meridian Bioscience, Inc
Meridian is a fully integrated life science company that develops markets and distributes a broad range of innovative diagnostic tests, purified reagents and related products and offers biopharmaceutical enabling technologies in more than 60 countries worldwide. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. For more information please visitwww.meridianbioscience.com.
John A. Kraeutler, Chief Executive Officer
illumigene® Mycoplasma Direct provides fast and accurate results in less than 1 hour for immediate and targeted treatment
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
VistaJet Ltd22.11.2017 11:40 | pressemeddelelse
VistaJet Partners With Christie's for the Global Tour of The Collection of Peggy and David Rockefeller
Nasdaq22.11.2017 10:03 | pressemeddelelse
Nasdaq to Deliver Blockchain e-Voting Solution to Strate
Oxford Immunotec21.11.2017 15:16 | pressemeddelelse
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference
Crown Bioscience Inc.21.11.2017 14:02 | pressemeddelelse
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs
OmniComm Systems Inc.21.11.2017 14:02 | pressemeddelelse
OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics
Nasdaq21.11.2017 11:32 | pressemeddelelse
Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum